Table 3.
Deterministic and probabilistic incremental cost-effectiveness ratios for symptom management versus glatiramer acetate
| Incremental costs ($US) | Incremental QALYsa | Deterministic ICER ($US) | Probabilistic ICER ($US) | % difference vs. EQ-5D | |
|---|---|---|---|---|---|
| Dutch utilities | |||||
| EQ-5D-3L utilities | 25,277 | 0.14 | 182,291 | 180,783 | |
| Mapped EQ-5D Versteegh et al. [10] | 25,277 | 0.1 | 245,363 | 246,071 | 36 |
| MSIS-PBM utilities | 25,277 | 0.09 | 289,514 | 289,814 | 60 |
| UK utilities | |||||
| EQ-5D-3L utilities | 25,277 | 0.16 | 153,476 | 140,736 | |
| Mapped EQ-5D Hawton et al. [12] | 25,277 | 0.14 | 170,771 | 169,383 | 20 |
| Mapped EQ-5D Versteegh et al. [10] | 25,277 | 0.13 | 194,445 | 193,327 | 37 |
| MSIS-8D utilities | 25,277 | 0.1 | 265,342 | 265,372 | 89 |
ICER incremental cost-effectiveness ratio, MSIS-8D eight-dimensional Multiple Sclerosis Impact Scale, MSIS-PBM Multiple Sclerosis Impact Scale Preference-based Measure, QALYs quality-adjusted life-years
aRounded values